Skip to main content

QNASL FDA Approval History

FDA Approved: Yes (First approved March 23, 2012)
Brand name: QNASL
Generic name: beclomethasone dipropionate
Dosage form: Nasal Aerosol
Company: Teva Pharmaceutical Industries Ltd.
Treatment for: Allergic Rhinitis

QNASL (beclomethasone dipropionate) is an intranasal corticosteroid non-aqueous "dry" spray formulation for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

Development timeline for QNASL

DateArticle
Dec 19, 2014Approval Teva Announces FDA Approval of QNASL for Children with Seasonal and Perennial Allergic Rhinitis
Mar 26, 2012Approval Teva Announces FDA Approval of QNASL (beclomethasone dipropionate), a New Nonaqueous Nasal Aerosol, for the Treatment of Allergic Rhinitis
Aug  8, 2011Teva Receives FDA Acceptance of Its New Drug Application for BDP Nasal HFA for the Treatment of Allergic Rhinitis

See also

QNASL (beclomethasone dipropionate) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer